DiagnoCure to host Q2 2013 earnings conference call and webcast
28 Mayo 2013 - 6:30AM
OTC Markets
DiagnoCure to host Q2 2013 earnings conference call and webcast
#ReleaseContent TABLE
{
BORDER-COLLAPSE: collapse
}
TR.cnwUnderlinedCell TD
{
BORDER-BOTTOM: #000000 1px solid
}
TR.cnwDoubleUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px double
}
TR.cnwBoldUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px solid
}
TD.cnwUnderlinedCell
{
BORDER-BOTTOM: #000000 1px solid
}
TD.cnwDoubleUnderlinedCell
{
BORDER-BOTTOM: #000000 3px double
}
TD.cnwBoldUnderlinedCell
{
BORDER-BOTTOM: #000000 3px solid
}
#ReleaseContent TABLE.cnwBorderedTable TD
{
BORDER-RIGHT: black 1px solid;
PADDING-RIGHT: 2px;
BORDER-TOP: black 1px solid;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
BORDER-LEFT: black 1px solid;
PADDING-TOP: 2px;
BORDER-BOTTOM: black 1px solid;
BORDER-COLLAPSE: collapse
}
#ReleaseContent TABLE TD
{
PADDING-RIGHT: 2px;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
PADDING-TOP: 2px
}
DiagnoCure to host Q2 2013 earnings conference call and webcast
PR Newswire
QUEBEC CITY, May 28, 2013
QUEBEC CITY, May 28, 2013 /PRNewswire/ -DiagnoCure Inc. (TSX:
CUR)
(OTCQX: DGCRF) announced today that it will release its second
quarter
2013 results on June 3, 2013, at
4:00 p.m. (EDT). DiagnoCure's
management will host a conference call the same day, at
4:30 p.m.
(EDT). Interested participants may listen to the call by
dialing
1-888-231-8191 or 514-807-9895 and referencing code 77464078
approximately 15 minutes prior to the call. The Corporation will
also
provide a live webcast of the call. Interested participants may
access
the webcast on DiagnoCure's website at www.diagnocure.com, through
a link on the Investors page - Presentations. A replay of
the
webcast will be available on DiagnoCure's website for those unable
to
participate in the live webcast.
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation
that
develops and commercializes high-value cancer diagnostic tests
that
increase clinician and patient confidence in making critical
treatment
decisions. In 2008, the Corporation launched a colorectal
cancer
staging test through its U.S. CLIA laboratory. PrevistageTM GCC
is
currently available for licensing. The Corporation has granted
a
worldwide exclusive license to Gen-Probe, now a wholly-owned
subsidiary
of Hologic Inc. operating as Hologic Gen-Probe, for the development
and
commercialization of a prostate cancer test using PCA3,
DiagnoCure's
proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA®
PCA3
test is commercialized in Europe
under CE mark and is approved for
commercialization in Canada and
the United States. For more
information, please visit www.diagnocure.com.
Forward?looking statements
This release contains forward?looking statements that involve known
and
unknown risks, uncertainties and assumptions that may cause
actual
results to differ materially from those expected. By their very
nature,
forward?looking statements are based on expectations and hypotheses
and
also involve risks and uncertainties, known and unknown, many of
which
are beyond DiagnoCure's control. As a result, investors are
cautioned
not to place undue reliance on these forward?looking statements.
The
forward-looking statements regarding the outcome of research
and
development projects, clinical studies and future revenues are
based on
management expectations. In addition, the reader is referred to
the
applicable general risks and uncertainties described in
DiagnoCure's
most recent Annual Information Form under the heading "Risk
Factors".
DiagnoCure undertakes no obligation to publicly update or revise
any
forward?looking statements contained herein unless required by
the
applicable securities laws and regulations.
SOURCE DiagnoCure inc.
Diagnocure (CE) (USOTC:DGCRF)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Diagnocure (CE) (USOTC:DGCRF)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
